Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687878 | 0.84 | TSHR (0.79) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL10344583 | 0.81 | MEN1 (0.65) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3765651 | 0.79 | TSHR (0.40) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL1451581 | 0.79 | POLB (0.55) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL1419142 | 0.79 | TSHR (0.50) | TSHRAPEX1TP53 | |
| Fenuron SCHEMBL8366971 | 0.78 | TSHR (0.64) | TSHRCA12CA1CA2CA9 | |
| Fenuron SCHEMBL10806698 | 0.78 | TSHR (0.64) | TSHRCA12CA1CA2CA9 | |
| Fenuron SCHEMBL62004 | 0.78 | TSHR (0.64) | TSHRCA12CA1CA2CA9 | |
| Fenuron SCHEMBL9451054 | 0.78 | TSHR (0.64) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3758922 | 0.78 | NPY5R (0.43) | TSHRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008518889-A | — | — | 2008-06-05 | — | — | JP | claimed |
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | claimed |
| EP-1812405-A1 | NOVEL BRADYKININ B1 ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-01 | — | — | EP | claimed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| WO-2006048209-A1 | NOVEL BRADYKININ B1 ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | WO | claimed |
| EP-2165830-B1 | Lithographic printing plate precursor and printing method using the same | FUJIFILM CORP (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100071574-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PRINTING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2165830-A1 | Lithographic printing plate precursor and printing method using the same | Fujifilm Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-09-06 | — | — | US | disclosed |
| EP-1812405-A1 | NOVEL BRADYKININ B1 ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| EP-0196617-A1 | [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same | SYNTEX (U.S.A.) INC. (US) | 1986-10-08 | — | — | EP | disclosed |
| EP-0192111-A1 | Iso-ureas, processes for their production and their use as herbicides | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
| US-4608388-A | Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0075117-B1 | 2H-1,2,4,6-THIATRIAZINE-1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1985-03-13 | — | — | EP | disclosed |
| US-4428766-A | 2N-1,2,4,6,Thiatriazine-1,1-dioxides and their use for controlling undesirable plant growth | BASF AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| EP-0075117-A2 | 2H-1,2,4,6-thiatriazine-1,1-dioxides, process for their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | disclosed |
| US-4139623-A | HYPOTENSIVE AGENTS | C-G CORP. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4027027-A | BETA-RECEPTOR-BLOCKERS, HYPOTENSIVES AND VALODILATORS; FOR TREATING ARRYTHMIAS AND ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | TSHR 1943/4885CA12 3508/4885CA1 2236/4885 |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | PPARA, PPARG, PPARD | TSHR 176/4885CA12 4450/4885CA1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.